U.S. Metals and Mining Stock News

NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

Is It Time To Reassess AMD (AMD) After Its Recent Share Price Pullback?

If you are wondering whether Advanced Micro Devices at around US$203 per share is still reasonable value or starting to look stretched, you are not alone. The stock has returned 6.4% over the last 7 days, while the 30 day and year to date returns are a 2.5% decline and a 9.1% decline respectively, set against a 1 year return of 110% and a 3 year return of 132.4%. Recent attention on AMD has focused on its role in high performance computing and graphics, alongside ongoing interest in...
NYSE:DDS
NYSE:DDSMultiline Retail

A Look At Dillard's (DDS) Valuation After Its New Limited Edition Style Collaboration

Limited-edition collaboration and fresh dividend decision draw attention to Dillard's stock Dillard's (DDS) has rolled out the Amanda Jones Vaughan x Antonio Melani limited-edition collection across its stores and website, and has also affirmed a regular cash dividend, giving investors fresh company specific developments to watch. See our latest analysis for Dillard's. Despite a recent 30 day share price return of a 10.25% decline and a 90 day share price return of an 18.14% decline from a...
NYSE:GE
NYSE:GEAerospace & Defense

How Investors Are Reacting To General Electric (GE) US$1 Billion U.S. Manufacturing Expansion Plan

GE Aerospace recently announced plans to invest US$1.00 billion across its U.S. manufacturing sites and supplier network in 2026, including upgrades at facilities in Terre Haute, Indiana, and Limestone County, Alabama, to boost jet engine and advanced materials production while adding 5,000 manufacturing and engineering jobs. This large manufacturing push, aimed at accelerating deliveries and easing a substantial engine order backlog, highlights how GE Aerospace is tying capital spending...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike Holdings (CRWD) Valuation Check After Recent Share Price Momentum And Short Term Pullback

Why CrowdStrike Holdings (CRWD) is on investors’ radar CrowdStrike Holdings (CRWD) has drawn attention recently as investors weigh its share price performance over the past month and past 3 months against its current revenue base and continuing net losses. See our latest analysis for CrowdStrike Holdings. The recent 7 day share price return of 11.47% and 30 day share price return of 10.32% contrast with a 90 day share price decline of 16.02%. At the same time, the 1 year total shareholder...
NasdaqGM:MDB
NasdaqGM:MDBIT

MongoDB (MDB) Valuation Check As Analyst Upgrades Meet Softer Guidance And Leadership Changes

MongoDB (MDB) is back in focus after a sharp selloff, with a recent upgrade from Scotiabank helping to shift sentiment that had weakened on cautious guidance and the announced departure of two senior go to market leaders. See our latest analysis for MongoDB. At a share price of $270.56, MongoDB has seen a 7-day share price return of 7.05% after a steep 30-day share price decline of 21.43%. The 1-year total shareholder return of 38.25% contrasts with weaker year-to-date share price...
NYSE:AGX
NYSE:AGXConstruction

How Investors May Respond To Argan (AGX) Powering Data Centers Amid Rising Insider Share Sales

Recently, Argan highlighted progress on a large 1.4 GW combined-cycle natural gas power plant project in Texas, reaching key notice-to-proceed milestones that reinforce its role in supplying critical power infrastructure for data-center demand. At the same time, a pick-up in insider share sales adds a layer of complexity for investors weighing Argan’s growing project visibility against internal shareholder behavior. Next, we’ll examine how the Texas power project milestone and data-center...
NYSE:XOM
NYSE:XOMOil and Gas

Exxon Mobil Legal Move To Texas Puts Governance And Shareholder Rights In Focus

Exxon Mobil's board has recommended relocating the company's legal domicile from New Jersey to Texas. The proposed move would align Exxon Mobil's legal home with its operating headquarters and core operations in Texas. The recommendation follows more than a century of the company being legally based in New Jersey. For shareholders watching Exxon Mobil (NYSE:XOM), the board's push to shift the legal base to Texas comes at a time when the shares trade around $148.13, with a return of 20.8%...
NasdaqGS:RMBS
NasdaqGS:RMBSSemiconductor

Assessing Rambus (RMBS) Valuation After Supply Chain Setback And Securities Investigation

Why Rambus Stock Is Back in Focus Rambus (RMBS) is in the spotlight after its February 2 update on a supply chain disruption affecting Q1 2026 performance, followed by a securities law investigation that has added another source of uncertainty for shareholders. See our latest analysis for Rambus. Rambus shares have been under pressure in recent months, with a 30 day share price return of 16.3% and a 90 day share price return of 16.1%, even as the 1 year total shareholder return sits at 73.8%...
NYSE:HPE
NYSE:HPETech

Hewlett Packard Enterprise (HPE) Q1 Profit Challenges Trailing Loss Narrative

Hewlett Packard Enterprise (HPE) opened fiscal Q1 2026 with revenue of US$9.3 billion and basic EPS of US$0.32. This compares with a trailing twelve month picture that includes a basic EPS loss of US$0.18 on revenue of US$35.7 billion. Over recent quarters the company has reported revenue of US$8.5 billion in Q4 2024, US$7.9 billion in Q1 2025, US$7.6 billion in Q2 2025, US$9.1 billion in Q3 2025, US$9.7 billion in Q4 2025 and now US$9.3 billion in Q1 2026. Quarterly basic EPS has ranged from...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback?

Roche’s persevERA Phase 3 breast cancer trial with giredestrant previously failed to meet its primary endpoint of improving progression-free survival, sparking renewed scrutiny of estrogen receptor–targeting therapies across the sector. Olema Pharmaceuticals’ separate palazestrant program, developed with Pfizer and Novartis and still in Phase 3 trials, has drawn attention as investors weigh whether its differentiated profile can set it apart from Roche’s setback. We’ll now look at how the...
NYSE:YEXT
NYSE:YEXTSoftware

Yext (YEXT) Profitability Turn Reinforces Bullish Narratives Despite Flat Quarterly Revenue

Yext (YEXT) has wrapped up FY 2026 with fourth quarter revenue of US$112.0 million and basic EPS of US$0.03, alongside trailing twelve month revenue of US$446.6 million and EPS of US$0.31 that reflect its move into profitability over the past year. The company has seen quarterly revenue hold in a tight band between US$109.5 million and US$113.1 million since early FY 2026, while basic EPS has ranged from US$0.01 in Q1 to US$0.22 in Q2, a clear shift from losses in FY 2025 where quarterly EPS...
NYSE:TMHC
NYSE:TMHCConsumer Durables

Taylor Morrison Backlog Slide Raises New Questions On Revenue And Margins

Taylor Morrison Home (NYSE:TMHC) is reporting a sharp decline in its order backlog after struggling to secure new home orders over the past two years. The company now faces expectations of lower revenue over the next 12 months, pointing to weaker demand conditions for its homebuilding operations. This shift in backlog and demand outlook marks a material change in operational momentum that has not been widely discussed yet. Taylor Morrison Home, a major US homebuilder focused on single...
NYSE:SEM
NYSE:SEMHealthcare

Is Select Medical Holdings (SEM) Pricing Look Justified After Mixed Returns And DCF Gap?

If you are wondering whether Select Medical Holdings is fairly priced or offering value at today’s levels, you are not alone. This article is built to help you judge the stock through a clear valuation lens. The share price closed at US$16.26 most recently, with returns of 0.0% over 7 days, 3.6% over 30 days, 9.7% year to date, a 2.5% decline over 1 year, a 26.2% gain over 3 years, and a 6.4% decline over 5 years. This gives a mixed picture for investors weighing risk and potential...
NasdaqGS:HLNE
NasdaqGS:HLNECapital Markets

Reassessing Hamilton Lane (HLNE) After Recent Share Price Weakness

Wondering if Hamilton Lane is attractively priced at around US$104.48, or if the market is asking too much for the shares right now? This article walks through that question step by step so you can judge the valuation for yourself. The stock has seen a 2.7% decline over the last 7 days, a 20.7% decline over the last 30 days, and a 23.5% decline year to date, while the 1 year return sits at a 24.3% decline and the 3 year and 5 year returns are 66.4% and 29.0% respectively. Those mixed results...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf Registration - And What's Next

In February 2026, Structure Therapeutics Inc. reported fourth-quarter 2025 results showing net income of US$33 million, compared with a net loss of US$36.48 million a year earlier. On the same day, the company also filed a US$235.64 million shelf registration for 3,541,890 American Depositary Shares tied to an employee stock plan, signaling preparations for potential future capital needs. We’ll now explore how this shift to quarterly profitability, alongside the new shelf registration,...
NYSE:FNF
NYSE:FNFInsurance

Reassessing Fidelity National Financial (FNF) Valuation After Recent Share Price Weakness

Event context and recent price moves Fidelity National Financial (FNF) has recently seen a 2.1% one day decline, adding to a 4.5% pullback over the past week and a steeper slide over the past month and past 3 months. In this context, the stock now sits at $48.40, with trailing 1 year total return at a 16.2% decline and year to date performance also in negative territory. This may prompt investors to revisit how current pricing lines up with fundamentals. See our latest analysis for Fidelity...
NYSE:VSCO
NYSE:VSCOSpecialty Retail

Assessing Victoria’s Secret (VSCO) Valuation After Volatile Reaction To Earnings Beat And Confident Guidance

Why Victoria's Secret stock is in focus after earnings and guidance Victoria's Secret (VSCO) is back in the spotlight after releasing quarterly results that exceeded earnings forecasts and paired strong sales with confident guidance for the coming quarter and full year 2026. The update has given investors fresh numbers to weigh, as the company outlines expectations for demand while also facing questions around profitability trends and ongoing decisions about its non core digital and styling...
NYSEAM:UEC
NYSEAM:UECOil and Gas

Uranium Energy (UEC) Q2 Loss Highlights Gap Between Forecast Profitability And Ongoing TTM Losses

Uranium Energy (UEC) has posted Q2 2026 revenue of US$20.2 million, with a basic EPS loss of US$0.03 and net income loss of US$13.9 million, providing a clear snapshot of where the business stands today. Over recent quarters, the company has reported revenue between US$0 and US$49.75 million while basic EPS has ranged from a loss of US$0.02 to a loss of US$0.07. This gives investors a wide view of how the top line and per-share results have shifted through different periods. With forecasts...
NasdaqGS:WDC
NasdaqGS:WDCTech

Is It Too Late To Consider Western Digital (WDC) After A 5x One Year Rally?

If you are wondering whether Western Digital's current share price still offers value after a big run, this article will walk through what the numbers are really saying about the stock. Western Digital recently closed at US$266.22, with a 6.2% return over the last 7 days, a 5.8% decline over 30 days, a 41.8% return year to date, and a very large 1-year gain of more than 5x. Recent headlines around Western Digital have focused on its position in data storage and memory solutions and how...
NasdaqGM:LFMD
NasdaqGM:LFMDHealthcare Services

LifeMD (LFMD) Trailing Losses Narrow To US$14.6m Challenging Bearish Profitability Narratives

LifeMD (LFMD) has wrapped up FY 2025 with Q4 revenue of about US$46.9 million and basic EPS of around a US$0.04 loss, alongside trailing twelve month revenue of roughly US$194.1 million and basic EPS of about a US$0.32 loss. Over the past few reported periods, revenue has moved from US$64.3 million in Q4 2024 to US$65.7 million in Q1 2025, then US$61.1 million in Q2, US$60.2 million in Q3 and US$46.9 million in Q4. Quarterly EPS shifted from roughly a US$0.02 loss in Q4 2024 to a small profit...
NYSE:MOS
NYSE:MOSChemicals

Mosaic (MOS) Valuation Revisited As Federal Fertilizer Price Fixing Probe Draws Scrutiny

Mosaic (MOS) is back in the spotlight as law firms review potential fiduciary duty issues tied to a federal probe into alleged fertilizer price fixing, raising fresh questions about legal risk and longer term shareholder exposure. See our latest analysis for Mosaic. At a share price of US$26.48, Mosaic has seen a 7.41% 1 month share price decline after legal headlines and mixed sentiment following its recent earnings report, even though the 90 day share price return of 11.49% and 1 year total...
NasdaqGS:DPZ
NasdaqGS:DPZHospitality

A Look At Domino’s (DPZ) Valuation After Strong Q4 Results And Berkshire Hathaway Interest

Domino's Pizza (DPZ) is back in focus after reporting strong fourth quarter results, with global retail sales growth, positive U.S. same store sales, and a 15% dividend increase catching investor attention. See our latest analysis for Domino's Pizza. Even with the latest quarterly update and dividend increase, Domino's recent share price performance has been mixed. The 1 month share price return is 1.43%, and the 1 year total shareholder return reflects a 5.49% decline. However, the 3 year...
NasdaqGS:PRLD
NasdaqGS:PRLDBiotechs

Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives

Prelude Therapeutics (PRLD) has just posted its FY 2025 numbers, with Q4 revenue of US$5.6 million, a basic EPS loss of US$0.21, and net income excluding extra items showing a loss of US$16.5 million. Over recent quarters the company has seen revenue move from US$4 million in Q4 2024 to US$6.5 million in Q3 2025 before landing at US$5.6 million in Q4 2025, while basic EPS has ranged from a loss of US$0.38 in Q4 2024 to a peak quarterly loss of US$0.42 in early 2025 and then US$0.21 in the...
NYSE:T
NYSE:TTelecom

AT&T’s US$250b Network Bet Tests Long Term Growth And Cash Flow

AT&T (NYSE:T) has announced a US$250b U.S. network investment initiative tied to the 150th anniversary of the telephone. The plan targets fiber, 5G, wireless, and satellite expansion, along with workforce development and AI-focused upskilling. The company also plans new public safety and network security efforts, as well as public private collaborations across all regions. For you as an investor, this marks one of the largest infrastructure commitments ever announced by AT&T, a core player...